Tag:

Bayer

Latest Headlines

Latest Headlines

Bayer fronting $155M for a promising anticoagulant from Isis Pharma

Bayer Healthcare is stepping up with $155 million in cash and a big near-term milestone in exchange for the development and commercialization rights to an experimental anticoagulant from Isis Pharmaceuticals.

UPDATED: Under FDA investigation, Bayer releases new data on Essure contraceptive with a positive twist

Under investigation by the FDA following claims of dangerous side effects and fraudulent clinical trial data, Bayer has released new data from a long-term study the German drugmaker says supports the safety and effectiveness of its Essure contraceptive inserts.

Biotech's boom spells a spike in R&D down payments

The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.

Bayer, Boehringer lead rapid rise in pharma's social media output

Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.

Bayer to close vet med plant, lay off 130

Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.

Careful, European drugmakers. Fitch says M&A may be a bit too heated

Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.

Bayer to pump $100M into U.S. facility focused on hemophilia drugs

Bayer said it will boost its already big footprint in the Bay Area with a $100 million investment in its Berkeley, CA, facility that is focused on developing new treatments for hemophilia.

Bayer pours $100M into Bay Area R&D with eyes on hemophilia

German drugmaker Bayer is investing $100 million in its Berkeley, CA, R&D outpost, blueprinting a new testing facility to support its work developing new treatments for hemophilia.

Bayer hits the gas on its top cancer prospect with Phase III in sight

Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.

CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals

Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.